FARE Welcomes Genentech as Sponsor to Support the Food Allergy Patient Journey
Sponsorship brings the potential for groundbreaking discoveries and solutions for the food allergy community
October 4, 2023 (McLean, VA) – FARE (Food Allergy Research & Education), the nation’s leading non-profit organization engaged in food allergy advocacy and largest private funder of food allergy research, is pleased to announce a significant strategic sponsorship with Genentech, a member of the Roche Group, a pioneering biotechnology company renowned for its commitment to scientific excellence and improving patient outcomes.
This sponsorship represents a substantial step forward in our mission to improve the quality of life and health of the 33 million Americans with life-threatening food allergies through transformative research, education and advocacy. Genentech's dedication to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases and our own pledge to improve the lives of the food allergy community create a powerful synergy that will drive innovation and lead to new solutions that benefit both healthcare professionals and patients.
This sponsorship will elevate the voice of the food allergy patient, educate patients on clinical options for their families, advance scientific discovery, and help to bring access and resources to traditionally underserved communities. FARE’s Health Equity work aligns with Genentech’s commitment to making a meaningful impact by addressing healthcare disparities and improving access to innovative treatments for underserved communities, ensuring that everyone has an equal opportunity to achieve better health outcomes. This sponsorship will enable FARE to expand its reach, provide increased support to individuals and families living with food allergies, and contribute to the development of innovative solutions that can ultimately transform the food allergy landscape.
“We are so excited to work with Genentech, a company known for its unwavering commitment to scientific innovation and improving patient lives,” remarked Sung Poblete, RN, PhD, CEO of FARE. “Together, we will bolster our ability to drive groundbreaking research to all who are impacted with this disease, develop life-saving therapies, and provide critical resources to those living with food allergies, and we will work tirelessly towards a future where food allergies are understood, preventable and treatable.”
To learn more about FARE and its mission, please visit foodallergy.org.
FARE (Food Allergy Research & Education) is the nation’s leading non-profit engaged in food allergy advocacy as well as the largest private funder of food allergy research. FARE’s innovative education, advocacy and research initiatives transform the future of food allergy through new and improved treatments and prevention strategies, effective policies and legislation, and novel approaches to managing the disease. To learn more, visit: foodallergy.org.